Effective litmus gene test for monitoring the quality of blood samples: Application to Alzheimer's disease diagnostics

Sung Mi Shim, Jong-Hoon Kim, Jae Pil Jeon

Research output: Contribution to journalArticle

Abstract

Gene expression profiles reflect the biologically diverse activities of cells under specific cell environments. Using the transcriptional response of cultured cells to blood composition, we developed a litmus gene assay to discriminate blood samples reflecting different sample qualities or disease conditions. This cell-based litmus gene assay identified six genes (CCL20, CEMIP, IL1B, IL8, PRG2, PTGS2) as potential biomarkers of plasma quality control and the SPC25 gene as a diagnostic biomarker of Alzheimer's disease (AD). In addition, the SPC25 gene expression level was significantly increased in the cell-based assay using serum samples from patients with mild cognitive impairment (MCI). In conclusion, we demonstrated the effectiveness and potential of a litmus gene assay to detect the orchestrated effects of circulating systemic factors, leading to the successful diagnosis of AD and MCI. This method is broadly applicable to the diagnosis of disease subtypes or patho-physiological stages of complex diseases and tumors.

Original languageEnglish
Article number16848
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Alzheimer Disease
Genes
Biomarkers
Cyclooxygenase 2
Interleukin-8
Transcriptome
Quality Control
Cultured Cells
Gene Expression
Serum
Neoplasms
Cognitive Dysfunction

ASJC Scopus subject areas

  • General

Cite this

Effective litmus gene test for monitoring the quality of blood samples : Application to Alzheimer's disease diagnostics. / Shim, Sung Mi; Kim, Jong-Hoon; Jeon, Jae Pil.

In: Scientific Reports, Vol. 7, No. 1, 16848, 01.12.2017.

Research output: Contribution to journalArticle

@article{42ea39e9452449ea8251b212afe08aa6,
title = "Effective litmus gene test for monitoring the quality of blood samples: Application to Alzheimer's disease diagnostics",
abstract = "Gene expression profiles reflect the biologically diverse activities of cells under specific cell environments. Using the transcriptional response of cultured cells to blood composition, we developed a litmus gene assay to discriminate blood samples reflecting different sample qualities or disease conditions. This cell-based litmus gene assay identified six genes (CCL20, CEMIP, IL1B, IL8, PRG2, PTGS2) as potential biomarkers of plasma quality control and the SPC25 gene as a diagnostic biomarker of Alzheimer's disease (AD). In addition, the SPC25 gene expression level was significantly increased in the cell-based assay using serum samples from patients with mild cognitive impairment (MCI). In conclusion, we demonstrated the effectiveness and potential of a litmus gene assay to detect the orchestrated effects of circulating systemic factors, leading to the successful diagnosis of AD and MCI. This method is broadly applicable to the diagnosis of disease subtypes or patho-physiological stages of complex diseases and tumors.",
author = "Shim, {Sung Mi} and Jong-Hoon Kim and Jeon, {Jae Pil}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-17293-2",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effective litmus gene test for monitoring the quality of blood samples

T2 - Application to Alzheimer's disease diagnostics

AU - Shim, Sung Mi

AU - Kim, Jong-Hoon

AU - Jeon, Jae Pil

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Gene expression profiles reflect the biologically diverse activities of cells under specific cell environments. Using the transcriptional response of cultured cells to blood composition, we developed a litmus gene assay to discriminate blood samples reflecting different sample qualities or disease conditions. This cell-based litmus gene assay identified six genes (CCL20, CEMIP, IL1B, IL8, PRG2, PTGS2) as potential biomarkers of plasma quality control and the SPC25 gene as a diagnostic biomarker of Alzheimer's disease (AD). In addition, the SPC25 gene expression level was significantly increased in the cell-based assay using serum samples from patients with mild cognitive impairment (MCI). In conclusion, we demonstrated the effectiveness and potential of a litmus gene assay to detect the orchestrated effects of circulating systemic factors, leading to the successful diagnosis of AD and MCI. This method is broadly applicable to the diagnosis of disease subtypes or patho-physiological stages of complex diseases and tumors.

AB - Gene expression profiles reflect the biologically diverse activities of cells under specific cell environments. Using the transcriptional response of cultured cells to blood composition, we developed a litmus gene assay to discriminate blood samples reflecting different sample qualities or disease conditions. This cell-based litmus gene assay identified six genes (CCL20, CEMIP, IL1B, IL8, PRG2, PTGS2) as potential biomarkers of plasma quality control and the SPC25 gene as a diagnostic biomarker of Alzheimer's disease (AD). In addition, the SPC25 gene expression level was significantly increased in the cell-based assay using serum samples from patients with mild cognitive impairment (MCI). In conclusion, we demonstrated the effectiveness and potential of a litmus gene assay to detect the orchestrated effects of circulating systemic factors, leading to the successful diagnosis of AD and MCI. This method is broadly applicable to the diagnosis of disease subtypes or patho-physiological stages of complex diseases and tumors.

UR - http://www.scopus.com/inward/record.url?scp=85037047820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037047820&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-17293-2

DO - 10.1038/s41598-017-17293-2

M3 - Article

C2 - 29203810

AN - SCOPUS:85037047820

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16848

ER -